PRINTER'S NO. 1795

THE GENERAL ASSEMBLY OF PENNSYLVANIA

SENATE RESOLUTION

No.

313

Session of

2024

INTRODUCED BY CAPPELLETTI, TARTAGLIONE, FONTANA, HUGHES,

SCHWANK, L. WILLIAMS, HAYWOOD, COSTA, BREWSTER, VOGEL AND

SAVAL, JUNE 30, 2024

and

WHEREAS, According to the World Health Organization, more

than 40 million people in the United States have migraine and

headache disorders, and in 2021, 40% of the population, or 3.1

billion people, were affected; and

WHEREAS, Headache disorders were globally found to be the

third leading cause of disability adjusted life years behind

stroke and dementia; and

WHEREAS, Attacks are often accompanied by one or more

symptoms, including visual disturbances, nausea, vomiting,

1.9 million veterans were diagnosed and treated within the VHA

for migraines and headaches; and

WHEREAS, Between 2008 and 2022, there was a 122% increase in

the number of veterans using Veterans Affairs Medical Centers

for headache care; and

WHEREAS, An estimated 350,000 service members have headaches

resulting from traumatic brain injuries sustained in combat; and

WHEREAS, The impact of migraines, headaches and cluster

attacks varies widely, showing distinct differences in how often

the attacks occur, the severity and the impact on daily life;

lasting for 4 to 72 hours on average; and

WHEREAS, The historical stigma and misinformation surrounding

headache diseases have impeded research and treatment

advancements, thus adequate research funding and public

education are crucial to addressing the serious and

incapacitating effects of migraine disease; and

WHEREAS, Individuals with one or more headache diseases or

comorbid medical conditions deserve equitable, affordable access

to new and innovative treatments; and

WHEREAS, The Senate is an institution that can raise